Hims & Hers Health, Inc. (NASDAQ:HIMS) shares are trading higher during Thursday’s premarket session after the company backed the FDA’s plans to clarify the regulatory status of peptide therapies and signaled efforts to expand access.
Regulatory Shift
Health Secretary RFK Jr. indicated that the FDA will ease restrictions on peptide injections, marking a shift from earlier rules that had limited their use due to safety concerns and a lack of human testing, Bloomberg reported.
The FDA now plans to review select peptides in July and may remove them from the high-risk list in the interim, potentially opening up a significant new revenue stream for companies like Hims that rely on compounding pharmacies.
FDA Clarity On Peptide Therapies
The company said the FDA’s move could shift peptide treatments out of the gray market into regulated channels overseen by healthcare professionals.
It added that it is actively exploring ways to expand access in alignment with FDA guidance, with a focus on consumer safety, transparency, and clinical standards.
Longevity Care Expansion
Hims & Hers said its medical team believes certain peptide therapies hold meaningful potential to help people live healthier lives.
The company is building a broader longevity care model spanning treatments, lab testing and hormonal health.
Analyst View And Financial Outlook
Separately, BofA Securities flagged downside risk to 2026 EBITDA, with GLP-1 contribution expected to decline by about 50%.
Analyst Allen Lutz maintained a Neutral rating and cut the price target to $21 from $23.
He cited margin pressure from a shift to branded GLP-1 treatments and a higher international revenue mix.
Lutz lowered his 2026 GLP-1 revenue estimate to $516 million from $577 million. He expects 40%–50% of subscribers to convert to branded offerings.
Eucalyptus generates about 90% of its revenue from branded GLP-1 distribution. This could create a 1–2 percentage point EBITDA margin headwind over a half-year period.
Critical Levels To Watch for HIMS Stock
The stock trades 26.8% above its 20-day SMA, signaling strong short-term momentum.
It remains 1.9% below its 100-day SMA, indicating an ongoing struggle to reclaim the intermediate trend.
The stock is down 9.87% over the past 12 months, reflecting a choppy broader trend despite the recent rebound. It remains well below the $70.43 52-week high and above the $13.74 52-week low.
This suggests the stock is still trading in the lower half of its one-year range.
- Key Resistance: $27.50 — a level where rallies have recently stalled.
- Key Support: $20.50 — near the 20-day SMA area where dip-buying has been showing up.
HIMS Earnings Preview for May 2026
Looking further out, the next major catalyst for the stock arrives with the May 11, 2026 (confirmed) earnings report.
- EPS Estimate: 5 cents (Down from 20 cents YoY)
- Revenue Estimate: $618.86 million (Up from $586.01 million YoY)
- Valuation: P/E of 47.6x (Indicates premium valuation relative to peers)
Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $25.39. Recent analyst moves include:
- TD Cowen: Hold (Lowers Target to $23.00) (March 27)
- Leerink Partners: Market Perform (Raises Target to $25.00) (March 16)
- Barclays: Overweight (Raises Target to $29.00) (March 11)
HIMS Stock Price Activity: Hims & Hers Health shares were up 9.63% at $26.63 during premarket trading on Thursday, according to Benzinga Pro data.
Photo: Shutterstock
Recent Comments